Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment-Reference-Cited by-同舟云学术

Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment

Published:2005-12-20 Issue:1 Volume:60 Page:110-118
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:

Author:

Dantoine T.,Auriacombe S.,Sarazin M.,Becker H.,Pere J-J,Bourdeix I.

Publisher

Hindawi Limited

Subject

General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1368-5031.2005.00769.x/fullpdf

Reference26 articles.

1. Selective loss of central cholinergic neurons in Alzheimer's disease;Davies;Lancet,1976

2. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease - a unified glutamatergic hypothesis on the mechanism of action;Danysz;Neurotox Res,2000

3. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology;Doody;Neurology,2001

4. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review;Clegg;Health Technol Assess,2001

5. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action;Poirier;Int J Clin Pract Suppl,2002

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Memantine-Based Derivatives: Synthesis and Their Biological Evaluation;Natural Product-based Synthetic Drug Molecules in Alzheimer's Disease;2023

2. Combination Therapy for the Treatment of Alzheimer’s Disease: Recent Progress and Future Prospects;Current Topics in Medicinal Chemistry;2022-09

3. Neuropharmacology in Alzheimer and Huntington Disease;Neurodegenerative Diseases: Multifactorial Degenerative Processes, Biomarkers and Therapeutic Approaches (First Edition);2022-08-09

4. A Synergistic Combination of DHA, Luteolin, and Urolithin A Against Alzheimer’s Disease;Frontiers in Aging Neuroscience;2022-02-16

5. Polypharmacology in Clinical Applications: Neurological Polypharmacology;Polypharmacology;2022